ZEVALIN
Total Payments
$317,755
Transactions
35
Doctors
33
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $38,500 | 1 | 0 |
| 2021 | $279,255 | 34 | 33 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $317,272 | 2 | 99.8% |
| Food and Beverage | $482.43 | 33 | 0.2% |
Payments by Type
Research
$317,272
2 transactions
General
$482.43
33 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| CD20-Targeted Systemic Radio-immunotherapy with Yttrium-90 Ibritumomab Tiuxetan for Low Grade Non-Hodgkin Lymphomas | Acrotech Biopharma LLC | $278,772 | 0 |
| IIS-ZEV-016 | Acrotech Biopharma Inc. | $38,500 | 0 |
Top Doctors Receiving Payments for ZEVALIN — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Hematology & Oncology | York, PA | $11.84 | 1 |
| , M.D | Hematology & Oncology | York, PA | $11.84 | 1 |
| , CRNP | Family | York, PA | $11.84 | 1 |
| , ARNP | Adult Health | Arcadia, FL | $11.32 | 1 |
| , MD | Hematology | Sarasota, FL | $11.32 | 1 |
| , APRN | Registered Nurse | Orlando, FL | $11.32 | 1 |
| , MD | Medical Oncology | Sarasota, FL | $11.32 | 1 |
| , M.D | Internal Medicine | Sarasota, FL | $11.32 | 1 |
| , DO | Medical Oncology | Fort Myers, FL | $11.17 | 1 |
Ad
Manufacturing Companies
- Acrotech Biopharma LLC $279,255
- Acrotech Biopharma Inc. $38,500
Product Information
- Type Drug
- Total Payments $317,755
- Total Doctors 33
- Transactions 35
About ZEVALIN
ZEVALIN is a drug associated with $317,755 in payments to 33 healthcare providers, recorded across 35 transactions in the CMS Open Payments database. The primary manufacturer is Acrotech Biopharma LLC.
Payment data is available from 2021 to 2024. In 2024, $38,500 was paid across 1 transactions to 0 doctors.
The most common payment nature for ZEVALIN is "Unspecified" ($317,272, 99.8% of total).
ZEVALIN is associated with 2 research studies, including "CD20-Targeted Systemic Radio-immunotherapy with Yttrium-90 Ibritumomab Tiuxetan for Low Grade Non-Hodgkin Lymphomas" ($278,772).